{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:02:38Z","timestamp":1783497758949,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.dld.2017.09.002","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T10:30:20Z","timestamp":1505212220000},"page":"1289-1297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-7063","authenticated-orcid":false,"given":"C\u00e2ndida","family":"Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2017.09.002_bib0005","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.crohns.2012.06.012","article-title":"Meningococcal meningoencephalitis after certolizumab pegol treatment in a patient with Crohn\u2019s disease","volume":"7","author":"Majumder","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2017.09.002_bib0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1086\/605498","article-title":"Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors","volume":"49","author":"Bradford","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/JCM.02052-08","article-title":"Fatal Epstein?Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn\u2019s disease","volume":"47","author":"N\u2019Guyen","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.dld.2017.09.002_bib0020","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/j.crohns.2013.03.004","article-title":"Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population","volume":"7","author":"Abreu","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2017.09.002_bib0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2017.09.002_bib0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.09.002_bib0035","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.09.002_bib0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/apt.13195","article-title":"Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases","volume":"41","author":"Ananthakrishnan","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2017.09.002_bib0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPG.0000000000001188","article-title":"NASPGHAN clinical report: surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-a inhibitors","volume":"63","author":"Ardura SST","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.dld.2017.09.002_bib0050","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/cid\/cix079","article-title":"Contribution to Clostridium difficile transmission of symptomatic patients with toxigenic strains who are fecal toxin negative","volume":"64","author":"Mawer","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0055","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11940-012-0172-y","article-title":"Complications of immunosuppressive\/immunomodulatory therapy in neurological diseases","volume":"14","author":"Nath","year":"2012","journal-title":"Curr Treat Options Neurol"},{"issue":"7","key":"10.1016\/j.dld.2017.09.002_bib0060","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0065","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"10.1016\/j.dld.2017.09.002_bib0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/0956462416675109","article-title":"Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals","volume":"28","author":"Fink","year":"2016","journal-title":"Int J STD AIDS"},{"issue":"2","key":"10.1016\/j.dld.2017.09.002_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2017.09.002_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian\u2013Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2017.09.002_bib0085","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.dld.2017.09.002_bib0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.09.002_bib0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2017.09.002_bib0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4292\/wjgpt.v7.i3.387","article-title":"What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?","volume":"7","author":"Andrisani","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.dld.2017.09.002_bib0105","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.dld.2017.09.002_bib0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bmt.1705289","article-title":"Preemptive diagnosis and treatment of Epstein\u2013Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development","volume":"37","author":"Weinstock","year":"2006","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.dld.2017.09.002_bib0115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.gastro.2013.09.035","article-title":"Lymphoma: the bete noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.09.002_bib0120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/art.11368","article-title":"Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review","volume":"49","author":"Dhote","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dld.2017.09.002_bib0125","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ibd.20498","article-title":"Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy","volume":"14","author":"Domenech","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00000478-200403000-00009","article-title":"Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study","volume":"28","author":"Kambham","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.dld.2017.09.002_bib0135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/rmv.362","article-title":"Varicella-zoster virus latency in human ganglia","volume":"12","author":"Kennedy","year":"2002","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.dld.2017.09.002_bib0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","article-title":"Infection risk in patients on multiple sclerosis therapeutics","volume":"29","author":"Williamson","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.dld.2017.09.002_bib0145","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cid\/cit376","article-title":"Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients","volume":"57","author":"Fine","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0150","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/j.1572-0241.2004.41389_7.x","article-title":"Disseminated primary varicella after initiation of infliximab for Crohn\u2019s disease","volume":"99","author":"Leung","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2017.09.002_bib0155","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0399-8320(06)73573-4","article-title":"Severe varicella infection during treatment with infliximab for Crohn\u2019s disease","volume":"30","author":"Tougeron","year":"2006","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.dld.2017.09.002_bib0160","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/ecco-jcc\/jjv143","article-title":"Varicella complicated by severe pneumonia and shock in an immunosuppressed Crohn\u2019s disease patient under azathioprine and anti-tumour necrosis factor alpha","volume":"9","author":"Abreu","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2017.09.002_bib0165","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0170","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.dld.2017.09.002_bib0175","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.dld.2017.09.002_bib0180","doi-asserted-by":"crossref","first-page":"h6747","DOI":"10.1136\/bmj.h6747","article-title":"Tuberculosis-diagnosis, management, prevention, and control: summary of updated NICE guidance","volume":"352","author":"Hoppe","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2017.09.002_bib0185","series-title":"Guidelines on the management of latent tuberculosis infection","year":"2015"},{"issue":"12","key":"10.1016\/j.dld.2017.09.002_bib0190","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.dld.2016.08.107","article-title":"The tuberculin skin test still matters for the screening of latent tuberculosis infections among inflammatory bowel disease patients","volume":"48","author":"Abreu","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0195","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0200","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/ciu796","article-title":"Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study","volume":"60","author":"Munoz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0205","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.dld.2017.09.002_bib0210","first-page":"253","article-title":"Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy","volume":"37","author":"Duarte","year":"2012","journal-title":"Acta Reumatol Portuguesa"},{"key":"10.1016\/j.dld.2017.09.002_bib0215","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00054725-200409000-00028","article-title":"Guidelines for immunizations in patients with inflammatory bowel disease","volume":"10","author":"Sands","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0220","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.dld.2017.09.002_bib0225","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/j.amepre.2015.09.008","article-title":"Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines","volume":"49","author":"Pilishvili","year":"2015","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.dld.2017.09.002_bib0230","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.dld.2017.09.002_bib0235","first-page":"1","article-title":"Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2013\u20132014","volume":"62","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.dld.2017.09.002_bib0240","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2011.11.109","article-title":"Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review","volume":"30","author":"Agarwal","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.dld.2017.09.002_bib0245","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0250","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2017.09.002_bib0255","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4254\/wjh.v7.i24.2503","article-title":"Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine","volume":"7","author":"Walayat","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.dld.2017.09.002_bib0260","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJM199701163360307","article-title":"Vaccines to prevent viral hepatitis","volume":"336","author":"Lemon","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2017.09.002_bib0265","first-page":"1080","article-title":"Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.dld.2017.09.002_bib0270","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tmaid.2006.04.004","article-title":"A review of the long-term protection after hepatitis A and B vaccination","volume":"5","author":"Van Damme","year":"2007","journal-title":"Travel Med Infect Dis"},{"issue":"Suppl. 5","key":"10.1016\/j.dld.2017.09.002_bib0275","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.dld.2017.09.002_bib0280","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1365-2036.2009.03973.x","article-title":"Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine","volume":"29","author":"Seksik","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2017.09.002_bib0285","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.dld.2017.09.002_bib0290","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination\u2014updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.dld.2017.09.002_bib0295","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MPG.0b013e3181bab351","article-title":"Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy","volume":"50","author":"Lu","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.dld.2017.09.002_bib0300","first-page":"212","article-title":"FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.dld.2017.09.002_bib0305","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/10489140-000000000-00000","article-title":"Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults","volume":"27","author":"Sanford","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.dld.2017.09.002_bib0310","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2017.09.002_bib0315","first-page":"504","article-title":"Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression","volume":"8","author":"Dezfoli","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.dld.2017.09.002_bib0320","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1097\/MIB.0b013e318281f562","article-title":"Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered","volume":"19","author":"Okafor","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.medmal.2014.01.007","article-title":"Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients","volume":"44","author":"Roux","year":"2014","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.dld.2017.09.002_bib0330","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","article-title":"Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients","volume":"17","author":"Rodriguez","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.dld.2017.09.002_bib0335","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.09.002_bib0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.dld.2017.09.002_bib0345","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr Opin Infect Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817310642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817310642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T18:31:54Z","timestamp":1659465114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865817310642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1590865817310642"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2017.09.002","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2017.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}